Sera Prognostics, Inc. (SERA)
Sera Prognostics, Inc. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Salt Lake City, UT, US. The stock last traded at $1.98, down 0.75% on the session, giving a market capitalisation of $75.4M. On trailing twelve-month figures it carries a trailing P/E of -3.04, a net margin of -56386.0%. Its beta of 0.98 implies it has historically moved less than the broad market.
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.
Sera Prognostics, Inc. is most often compared with the following Healthcare names: